SS-31肽防治模型动物心力衰竭的疗效与安全性系统评价  

Efficacy and Safety of SS-31 Peptide in Treating Heart Failure:A Systematic Review of Animal Models

作　　者：耿彦婷[1] 褚瑜光[1] 胡元会[1] 宋庆桥[1] 师帅[1] 李可[2] 

机构地区：[1]中国中医科学院广安门医院,北京100053 [2]北京中医药大学

出　　处：《中西医结合心脑血管病杂志》2016年第18期2143-2146,共4页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

基　　金：国家自然科学基金面上项目(No.81373833)

摘　　要：目的系统评价SS-31肽防治模型动物心力衰竭的疗效及安全性。方法计算机检索PubMed、Embase、OVID、CBM、CNKI、VIP及WanFang Data等数据库,手动检索参考文献,纳入SS-31肽防治心力衰竭的动物实验。结局评价包括心肌舒缩功能、血流动力学改变、BNP(或NT-proBNP)水平、心室重塑、氧化应激损伤、不良反应及不良事件。由两名研究者独立评价纳入研究的质量、提取数据并交叉核对,使用RevMan 5.2软件进行Meta分析。结果显示:3/49篇文献经剔重、初筛及全文复筛纳入。纳入研究中,3篇文献均报道了SS-31肽对心衰模型动物心肌舒缩功能的影响,表明SS-31肽对心衰模型动物左室舒张末内径、每搏输出量及射血分数的变化均具一定的良性干预作用。但基于2篇文献中左室短轴缩短率(LVFS)比较的Meta分析,结果提示SS-31肽对心衰模型动物LVFS的改善无显著作用[SMD=7.18,95%CI(-1.91,16.26),P=0.12]。1篇文献报道表明SS-31肽对心衰模型动物血流动力学相关病理改变无显著影响。2篇报道SS-31肽干预心衰模型动物心室重塑疗效的研究结果存在异质性。3篇文献均报道了SS-31肽治疗对心衰模型动物氧化应激损伤的改善作用,且均显示出确切的干预疗效。纳入研究均未报道SS-31肽治疗对BNP(或NT-proBNP)水平的影响,亦未见药物不良反应的相关报道。1篇文献报道了动物死亡事件的发生率,提示药物干预过程中无严重不良事件的发生。结论 SS-31肽对模型动物心力衰竭的防治具有潜在的疗效,但因证据单薄,目前尚无法得到较为可靠的结论。Objective To assess the efficacy and safety of Szeto-Schiller（SS）-31 peptide for heart failure based on animal models.Methods We searched PubMed,Embase,OVID,CBM,CNKI,VIP,WanFang Data,and references were hand searched.All researches based on animal models of treating heart failure with SS-31 peptide versus sham groups were included.Outcome measurements included cardiac systolic and diastolic function,hemodynamic changes,B-type natriuretic peptide（BNP）or N-terminal B-type natriuretic peptide precursor（NT-proBNP）level,cardiac remodeling,oxidative stress injury,adverse effects and events.Data were extracted independently by two reviewers.Results Three of the 49 articles were included through eliminating duplications,title/abstract screening and full-text review.Three articles which reported the curative effect of SS-31 peptide in improving cardiac systolic and diastolic function indicated the marked curative effect on left ventricular end diastolic diameter（LVEDD）,stroke volume and ejection fraction,while the Meta-analysis result of LVFS showed no statistical difference between the model group and SS-31 peptide treatment group[SMD =7.18,95%CI（-1.91,16.26）,P =0.12].One article reported no significant changes of hemodynamic findings after the intervention of SS-31.The outcomes existed heterogeneity between the 2 articles reported the efficiency of SS-31 peptide in alleviating cardiac fibrosis.Three articles reported the improvement of myocardial oxidative stress injury in animal models through the administration of SS-31 peptide.None of the included articles reported the level of BNP（or NT-proBNP）nor SS-31 peptide related adverse effect.Based on the report of animal deaths from1 article,showed no severe adverse events happened during the administration course.Conclusion SS-31 peptide shows potential efficiency on heart failure,but the evidence was limited at present to reach a reliable conclusion.

关 键 词：心力衰竭 SS-31肽 BendaviaTM 动物 系统评价 

分 类 号：R541.6[医药卫生—心血管疾病] R256.2[医药卫生—内科学]